BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 26351648)

  • 21. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
    Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
    Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual colonization by vaccine serotypes in rural South Africa four years following initiation of pneumococcal conjugate vaccine immunization.
    Madhi SA; Nzenze SA; Nunes MC; Chinyanganya L; Van Niekerk N; Kahn K; Twine R; De Gouveia L; Von Gottberg A; Shiri T
    Expert Rev Vaccines; 2020 Apr; 19(4):383-393. PubMed ID: 32237932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
    Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
    Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media.
    Cohen R; Levy C; Bingen E; Koskas M; Nave I; Varon E
    Pediatr Infect Dis J; 2012 Mar; 31(3):297-301. PubMed ID: 22330166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation.
    Cohen R; Varon E; Doit C; Schlemmer C; Romain O; Thollot F; Béchet S; Bonacorsi S; Levy C
    Vaccine; 2015 Sep; 33(39):5118-26. PubMed ID: 26271823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 13-valent pneumococcal conjugate vaccine (PCV13).
    Jefferies JM; Macdonald E; Faust SN; Clarke SC
    Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
    Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
    Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2016 Aug; 34(36):4313-20. PubMed ID: 27422342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.